CTLA4 and metastatic melanoma: The concurrent inhibition of cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and PD-L1 has demonstrated a synergistic effect in metastatic melanoma, enhancing efficacy Compared to mono therapeutic approaches.10